LDR vs. HDR Brachytherapy for Prostate Cancer

Launched by BRITISH COLUMBIA CANCER AGENCY · Feb 7, 2018

Keywords

ClinConnect Summary

This clinical trial is comparing two types of treatments for prostate cancer: low dose rate (LDR) and high dose rate (HDR) brachytherapy. Both treatments involve placing radioactive seeds or sources directly into the prostate to help destroy cancer cells. The trial is specifically looking at men who have favorable or low-tier intermediate-risk prostate cancer, meaning their cancer is less aggressive and they are expected to live at least 10 more years.

To participate in this trial, men must meet certain criteria, such as having specific prostate cancer stages and levels of a blood test called PSA, and they cannot have had previous surgeries or treatments for prostate cancer. Participants will receive one of the two treatments and will be monitored throughout the study to see how well each method works. The trial is currently recruiting participants, so if you or someone you know fits the eligibility requirements, it could be an opportunity to contribute to important research in prostate cancer treatment.

Gender

MALE

Eligibility criteria

• Inclusion Criteria:
• • Favorable risk and low-tier intermediate-risk prostate cancer with estimated life expectancy of at least 10 years.
• • Clinical stage T1c-T2b, PSA \< 20, Gleason \< 8
• • ECOG 0-1
• • Low tier intermediate-risk prostate cancer is defined by a single NCCN intermediate risk factor
• * Extensive favorable-risk disease is defined as:
• • clinical stage T1c-T2a
• • PSA \< 10
• • Gleason 6
• • ≥ 50% of biopsy cores containing cancer
• • PSA density \> 0.2 ng/cc
• • Selected intermediate risk patients not defined above
• • - T1c/T2a
• • - PSA \< 10
• • -Gleason 4+3
• • -\< 33% of cores involved
• • -Max tumor length in any core 10 mm
• • No androgen deprivation therapy (ADT)
• • Prostate volume by TRUS ≤ 60 cc.
• • Not eligible for, or accepting of, active surveillance according to NCCN guidelines.
• • Signed study specific informed consent.
• Exclusion Criteria:
• • Prior radical surgery for carcinoma of the prostate,
• • Prior pelvic radiation
• • Prior chemotherapy for prostate cancer,
• • Prior TURP or cryosurgery of the prostate
• • Claustrophobic or unable to undergo MRI